SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum. Here we report that prophy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiyu, Cui, Shuang, He, Qingxian, Guo, Yitong, Pan, Xiaojie, Zhang, Pengfei, Huang, Ningning, Ge, Chaoliang, Wang, Guangji, Gonzalez, Frank J., Wang, Hong, Hao, Haiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957516/
https://www.ncbi.nlm.nih.gov/pubmed/31932588
http://dx.doi.org/10.1038/s41467-019-14138-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957516/
https://www.ncbi.nlm.nih.gov/pubmed/31932588
http://dx.doi.org/10.1038/s41467-019-14138-6

Ejemplares similares